CureVac Presents Convincing Data From mRNA-Based Vaccine

CureVac GmbH, an mRNA vaccine company, have released first data from an open-label Phase I/IIa clinical trial of its mRNA vaccine CV9103 in patients.

CureVac GmbH, an mRNA vaccine company, have released first data from an open-label Phase I/IIa clinical trial of its mRNA vaccine CV9103 in patients with hormone-refractory prostate cancer with rising PSA and existing metastasis in the vast majority of patients. The trial was designed to assess safety and toxicity of CV9103, as well as its ability to induce antigen specific humoral and cellular immune responses in cancer patients. The results suggest that CV9103 is safe, well tolerated and biologically active. More than 70% of the study patients responded to at least one antigen out of the four antigens in CV9103. The trial evaluated a five dose regime of CV9103 delivered via intradermal injection in 44 patients.

The trial with CV9103, conducted in Germany and Italy, was the first to test a immunotherapy based on CureVac′s RNActive vaccination technology in